Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
Crossref DOI link: https://doi.org/10.1007/s13300-018-0371-y
Published Online: 2018-02-06
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Neslusan, Cheryl
Teschemaker, Anna
Willis, Michael
Johansen, Pierre
Vo, Lien
Funding for this research was provided by:
Janssen Global Services, LLC
Text and Data Mining valid from 2018-02-06
Article History
Received: 5 December 2017
First Online: 6 February 2018